BLU-5937, A Potent and Selective P2X3 Antagonist, For the Treatment of Chronic Itch: Evidence from Pre-Clinical Studies

被引：1
|
作者：
Chauret, N. [1 ]
Ase, A. R. [2 ]
Seguela, P. [2 ]
Liu, X. Y. [3 ]
Matzouranis, T. [1 ]
Garceau, D. [1 ]
机构：
[1] Bellus Hlth Inc, Laval, PQ, Canada
[2] Mc Gill, MNI, Montreal, PQ, Canada
[3] Univ Washington, St Louis, MO USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2019年 / 139卷 / 09期
关键词：
D O I：
10.1016/j.jid.2019.07.110
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
106
引用
收藏
页码：S232 / S232
页数：1
相关论文
共 50 条
  • [1] BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration
    Garceau, Denis
    Chauret, Nathalie
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2019, 56 : 56 - 62
  • [2] Evaluation of the In Vitro Potency and Selectivity of the P2X3 Receptor Antagonist Camlipixant (BLU-5937)
    Filion, Mario
    Chauret, Nathalie
    Garceau, Denis
    LUNG, 2023, 201 : 2 - 3
  • [3] BLU-5937 a Highly Selective P2X3 Homotrimeric Receptor Antagonist with Improved Taste Safety Profile in Healthy Subjects
    Garceau, D.
    Chauret, N.
    Harvey, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [4] Design of SOOTHE, a Phase 2b Dose Finding Study with BLU-5937, a Selective P2X3 Antagonist, in Refractory Chronic Cough
    Bonuccelli, C. M.
    Smith, J.
    Birring, S. S.
    Blaiss, M.
    Dicpinigaitis, P.
    Sher, M. R.
    Garceau, D.
    Chauret, N.
    Garin, M.
    Harvey, L.
    Carroll, K. J.
    Shaw, J. E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [5] Determination of Camlipixant (BLU-5937) P2X3 antagonist activity in a sensory neuronal model and bronchial epithelial cells
    Dunne, Orla
    About, Imad
    Mcgarvey, Lorcan
    Lundy, Fionnuala
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [6] Burden of Cough in Refractory Chronic Cough Patients Enrolled in A Phase 2b Study of the P2X3 Antagonist BLU-5937
    Goldsobel, Alan
    Blaiss, Michael
    Sher, Mandel
    Birring, Surinder
    Smith, Jaclyn
    Harvey, Laurent
    Yang, Ronghua
    Bonuccelli, Catherine
    Garin, Margaret
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB161 - AB161
  • [7] PRIOR SPECIALIST CONSULTATIONS AND TREATMENTS IN A REFRACTORY CHRONIC COUGH POPULATION ENROLLED IN A PHASE 2B STUDY OF THE P2X3 ANTAGONIST BLU-5937
    Dicpinigaitis, Peter V.
    Mcgarvey, Lorcan
    Smith, Jaclyn A.
    Blaiss, Michael
    Iyer, Vivek N.
    Lanouette, Sylvain
    Yang, Ronghua
    Garin, Margaret
    Bonuccelli, Catherine M.
    CHEST, 2022, 162 (04) : 2487A - 2488A
  • [8] Improvements in Cough Frequency Over 24 Hours with BLU-5937, a Selective P2X3 Antagonist, in Patient Subgroups Defined by Baseline Awake Cough Frequencies
    Smith, J.
    Morice, A. H.
    Birring, S. S.
    Parker, S.
    Marsden, P. A.
    Holcomb, J.
    Prenner, B. M.
    Sher, M. R.
    Steven, G. C.
    Mcgarvey, L.
    Garceau, D.
    Bonuccelli, C. M.
    Harvey, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [9] Improvements in cough severity and cough-related quality of life in a phase 2 trial (RELIEF) with the P2X3 antagonist BLU-5937 in refractory chronic cough (RCC)
    Birring, Surinder S.
    Smith, Jaclyn A.
    Morice, Alyn H.
    Sher, Mandel
    Hull, James H.
    Goldsobel, Alan B.
    Lanouette, Sylvain
    Li, Ella
    Harvey, Laurent
    Bonuccelli, Catherine M.
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [10] BLU-5937, A Highly Selective P2X3 Homotrimeric Receptor Antagonist, Exhibits Excellent Pharmacokinetic and Safety Profile Including Improved Taste Safety Profile in Healthy Subjects
    Garceau, D.
    Chauret, N.
    Harvey, Laurent
    LUNG, 2020, 198 (01) : 38 - 39
12345